Momelotinib not checked

Sierra Oncology LLC - a GSK company · GSK3070785 · GS-0387

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 2 trial completes
Trials
5 active
11 in total · 5 in the EU
Targets
JAK1 · JAK2 · JAK3 · ACVR1 · TYK2
 

What this is

How it works
Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
Tested for
Primary Myelofibrosis (2 trials), VEXAS Syndrome, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis, Myelodysplastic Syndromes
Main trialPhase 2/3
“This study will assess the efficacy and safety of momelotinib in participants with a diagnosis of VEXAS.”In the company’s words, NCT07569081 on ClinicalTrials.gov
Other names
GSK3070785 · GS-0387 · CYT387 · MMB

Other drugs for Primary Myelofibrosis

All 37 drugs for Primary Myelofibrosis

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials11

TrialPhaseCompletesWhat it tests
Phase 2/3Not yet recruiting 6 Dec 2028 A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome
Phase 2Active, not recruiting 11 Dec 2026 Extended Access of Momelotinib in Adults With Myelofibrosis
Phase 2Recruiting 16 Mar 2027 Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Phase 2Recruiting 14 Jul 2027 A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome
Phase 3Completed 28 Jul 2016 Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
Phase 3Completed 12 Sep 2016 Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
Phase 3Terminated 10 Apr 2017 Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Phase 3Completed 3 Dec 2021 A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)
Phase 2Completed 18 Jul 2017 Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Phase 2Completed 6 Dec 2018 Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia
Phase 1/2Authorised not given Melanoma-TBK1-inhibitor enhanced Immuno Therapy with Checkpoint Inhibitors: a Phase IB/II Trial in Unresectable Stage III or Stage IV Cutaneous Melanoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Momelotinib

Following is part of Solo: you see every change to Momelotinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in